+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immunosuppressants Global Market Report 2021: COVID-19 Growth and Change to 2030

  • PDF Icon

    Report

  • 175 Pages
  • September 2021
  • Region: Global
  • The Business Research Company
  • ID: 5446132
Immunosuppressants Global Market Report 2021: COVID-19 Growth and Change to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global immunosuppressants market.







This report focuses on the immunosuppressants market which is experiencing strong growth. The report gives a guide to the immunosuppressants market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for immunosuppressants? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Immunosuppressants market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider immunosuppressants market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The immunosuppressants market section of the report gives context. It compares the immunosuppressants market with other segments of the immunosuppressants market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, immunosuppressants indicators comparison.

Scope


Markets Covered:


  • By Drug Class: Corticosteroids; Monoclonal Antibodies (mAbs); Calcineurin Inhibitors; mTOR Inhibitors; Anti-Proliferative Agents; Others
  • By Indication: Organ Transplantation; Autoimmune Disorders; Non-Autoimmune Inflammatory Diseases
  • By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Companies Mentioned:


Astellas Pharma; GlaxoSmithKline; Bristol Myers Squibb; Johnson & Johnson; Intas Pharmaceuticals Ltd.

Countries:


Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions:


Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series:


Five years historic and ten years forecast.

Data:


Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data segmentations:


Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing:


Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Immunosuppressants Market

What is the estimated value of the Global Immunosuppressants Market?

The Global Immunosuppressants Market was estimated to be valued at $16.5 billion in 2021.

What is the growth rate of the Global Immunosuppressants Market?

The growth rate of the Global Immunosuppressants Market is 11.3%, with an estimated value of $25.33 billion by 2025.

What is the forecasted size of the Global Immunosuppressants Market?

The Global Immunosuppressants Market is estimated to be worth $25.33 billion by 2025.

Who are the key companies in the Global Immunosuppressants Market?

Key companies in the Global Immunosuppressants Market include Astellas Pharma, GlaxoSmithKline, Bristol Myers Squibb, Johnson & Johnson, Intas Pharmaceuticals Ltd., Mylan Laboratories Inc, Pfizer, Novartis and Sanofi S.A.

Table of Contents

1. Executive Summary2. Immuno Suppressive Drugs Market Characteristics3. Immuno Suppressive Drugs Market Trends and Strategies4. Impact Of COVID-19 On Immuno Suppressive Drugs
5. Immuno Suppressive Drugs Market Size and Growth
5.1. Global Immuno Suppressive Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Immuno Suppressive Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Immuno Suppressive Drugs Market Segmentation
6.1. Global Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Corticosteroids
  • Monoclonal Antibodies (mAbs)
  • Calcineurin Inhibitors
  • mTOR Inhibitors
  • Anti-Proliferative Agents
  • Others
6.2. Global Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Organ Transplantation
  • Autoimmune Disorders
  • Non-Autoimmune Inflammatory Diseases
6.3. Global Immuno Suppressive Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

7. Immuno Suppressive Drugs Market Regional and Country Analysis
7.1. Global Immuno Suppressive Drugs Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Immuno Suppressive Drugs Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8. Asia-Pacific Immuno Suppressive Drugs Market
8.1. Asia-Pacific Immuno Suppressive Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
9. China Immuno Suppressive Drugs Market
9.1. China Immuno Suppressive Drugs Market Overview
9.2. China Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
10. India Immuno Suppressive Drugs Market
10.1. India Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11. Japan Immuno Suppressive Drugs Market
11.1. Japan Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Australia Immuno Suppressive Drugs Market
12.1. Australia Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13. Indonesia Immuno Suppressive Drugs Market
13.1. Indonesia Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14. South Korea Immuno Suppressive Drugs Market
14.1. South Korea Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15. Western Europe Immuno Suppressive Drugs Market
15.1. Western Europe Immuno Suppressive Drugs Market Overview
15.2. Western Europe Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16. UK Immuno Suppressive Drugs Market
16.1. UK Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17. Germany Immuno Suppressive Drugs Market
17.1. Germany Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18. France Immuno Suppressive Drugs Market
18.4. France Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19. Eastern Europe Immuno Suppressive Drugs Market
19.1. Eastern Europe Immuno Suppressive Drugs Market Overview
19.2. Eastern Europe Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20. Russia Immuno Suppressive Drugs Market
20.1. Russia Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21. North America Immuno Suppressive Drugs Market
21.1. North America Immuno Suppressive Drugs Market Overview
21.2. North America Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22. USA Immuno Suppressive Drugs Market
22.1. USA Immuno Suppressive Drugs Market Overview
22.2. USA Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23. South America Immuno Suppressive Drugs Market
23.1. South America Immuno Suppressive Drugs Market Overview
23.2. South America Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24. Brazil Immuno Suppressive Drugs Market
24.1. Brazil Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25. Middle East Immuno Suppressive Drugs Market
25.1. Middle East Immuno Suppressive Drugs Market Overview
25.2. Middle East Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26. Africa Immuno Suppressive Drugs Market
26.1. Africa Immuno Suppressive Drugs Market Overview
26.2. Africa Immuno Suppressive Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Immuno Suppressive Drugs Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
27. Immuno Suppressive Drugs Market Competitive Landscape and Company Profiles
27.1. Immuno Suppressive Drugs Market Competitive Landscape
27.2. Immuno Suppressive Drugs Market Company Profiles
27.2.1. Astellas Pharma
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. GlaxoSmithKline
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Bristol Myers Squibb
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Johnson & Johnson
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Intas Pharmaceuticals Ltd.
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Immuno Suppressive Drugs Pipeline Analysis29. Key Mergers and Acquisitions in the Immuno Suppressive Drugs Market30. Immuno Suppressive Drugs Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright and Disclaimer

Executive Summary

Major players in the immunosuppressant market are Astellas Pharma, GlaxoSmithKline, Bristol Myers Squibb, Johnson & Johnson, Intas Pharmaceuticals Ltd., Mylan Laboratories Inc, Pfizer, Novartis, Novartis AG, and Sanofi S.A.

The global immunosuppressants market is expected to grow from $15.04 billion in 2020 to $16.5 billion in 2021 at a compound annual growth rate (CAGR) of 9.7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $25.33 billion in 2025 at a CAGR of 11%.

The immunosuppressant market consists of sales of immunosuppressants or anti-rejection drugs generated by companies manufacturing immunosuppressant drugs. Immunosuppressants are medicinal substances that prevent or inhibit activity in the immune system. Immunosuppressive drugs are mainly used in organ transplantation procedures and also in the treatment of certain autoimmune diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, and others.

The immunosuppressants market covered in this report is segmented by drug class into corticosteroids, monoclonal antibodies (MABs), calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, others. It is also segmented by indication into organ transplantation, autoimmune disorders, non-autoimmune inflammatory diseases and by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Stringent government regulations are expected to hamper the growth of the market. Regulators such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) maintain public safety for food and drugs through a stringent regulatory drug approval process. For an immunosuppressant drug to be approved by the regulatory authorities, the sponsor must provide satisfactory evidence regarding the safety and efficacy of a drug in a patient with a defined clinical condition. Sponsors should submit to the Center for Drug Evaluation and Research (CDER) any information on the immunotoxicology evaluation of drugs whenever such information becomes available, for review. Many guidelines have also been adopted by the EU including those providing general guidance, more specific guidance on quality issues, and non-clinical and clinical aspects. Therefore, the stringent regulatory and approval process on immunosuppressant drugs are projected to hamper the overall growth of the immunosuppressants market.

In 2019, AbbVie, an American publicly-traded biopharmaceutical company, acquired Allergan for $63 billion. The transaction significantly expanded and diversified AbbVie's revenue base and existing leadership position in immunology with humira and recently launched skyrizi and rinvoq, and hematologic oncology with imbruvica and venclexta. Allergan provides new growth opportunities in neuroscience, with Botox therapeutics, Vraylar, and Ubrelvy and a global aesthetics business, with leading brands including Botox and Juvéderm. Allergan is an Irish-domiciled pharmaceutical company that develops, manufactures, and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology.

The surge in organ transplant procedures such as kidney transplant and liver transplant due to the rise in incidences of organ failure is the major factor driving the immunosuppressant market growth. According to the United Network for Organ Sharing (UNOS), 39,718 organ transplants were performed in 2019 in the United States, and as of March 2020, there are more than 112,000 candidates on the U.S. national transplant waiting list, waiting for an organ transplant. According to the Global Liver Institute’s 2019 report, there are 13,192 liver patients in the U.S. waiting for a lifesaving transplant. The increasing number of cases of organ transplants and organ failure incidences in patients are, therefore, expected to drive the market growth.

The phenotypic personalized medicine or PPM or a hybrid of artificial intelligence and physician intervention is a new approach to overcome the issues with immunosuppressants. For instance, Tacrolimus is the most widely used immunosuppressant for patients who are undergoing organ transplantation. When the patient is in the hospital, Tacrolimus immunosuppressant levels must be checked regularly and changed frequently. PPM approach that is based on a computational platform is used to overcome this concern. The inputs from the computational platform-based PPM approach includes the past response of the patient to the dose of the drug and other drugs that are being taken, and current data on liver and kidney. Using PPM, the physician can identify the optimal drug and dose combination from various possibilities. Therefore, it is believed that artificial intelligence is leading the way to not only more personalized and effective drug dosing but also enhancing physicians’ decision-making capabilities by providing clinical data rather than predicted responses.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Astellas Pharma
  • GlaxoSmithKline
  • Bristol Myers Squibb
  • Johnson & Johnson
  • Intas Pharmaceuticals Ltd.
  • Mylan Laboratories Inc
  • Pfizer
  • Novartis
  • Novartis AG
  • Sanofi S.A
  • F. Hoffmann La Roche Ltd
  • Zydus Cadila
  • Accord Healthcare
  • Genzyme
  • AbbVie Inc.
  • Glenmark Pharmaceuticals
  • Akriti Pharmaceuticals Pvt.
  • Allergan
  • Sebela Pharmaceuticals Inc.
  • Healthy Life Pharma Private Limited
  • RPG Life Sciences Limited

Methodology

Loading
LOADING...